Search

How Can We Help You?

Video

Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Ovarian Cancer Trials

Select Clinical Trial

Protocol Number: ImmunoGen/GOG 3045

Protocol Title: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Eligibility: Women ≥ 18 years of age with a confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer.  Patients must have platinum-resistant disease.

Contact Information: (910) 715-2200

___________________________________________________________________________________________

Protocol Number: Aravive AVB500-OC-004/GOG 3059

Protocol Title:  A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer. 

Eligibility: Women 18 years of age or older with confirmed recurrent, platinum-resistant, high-grade serious ovarian, fallopian tube, or peritoneal cancer.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Specialties
Clara McLean House
Make a Donation
News & Events